Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Stephanie T H PeetersJ V Lebesque

Abstract

To determine whether a dose of 78 Gy improves outcome compared with a conventional dose of 68 Gy for prostate cancer patients treated with three-dimensional conformal radiotherapy. Between June 1997 and February 2003, stage T1b-4 prostate cancer patients were enrolled onto a multicenter randomized trial comparing 68 Gy with 78 Gy. Patients were stratified by institution, age, (neo)adjuvant hormonal therapy (HT), and treatment group. Four treatment groups (with specific radiation volumes) were defined based on the probability of seminal vesicle involvement. The primary end point was freedom from failure (FFF). Failure was defined as clinical failure or biochemical failure, according to the American Society of Therapeutic Radiation Oncology definition. Other end points were freedom from clinical failure (FFCF), overall survival (OS), and toxicity. Median follow-up time was 51 months. Of the 669 enrolled patients, 664 were included in the analysis. HT was prescribed for 143 patients. FFF was significantly better in the 78-Gy arm compared with the 68-Gy arm (5-year FFF rate, 64% v 54%, respectively), with an adjusted hazard ratio of 0.74 (P = .02). No significant differences in FFCF or OS were seen between the treatment arms. There...Continue Reading

References

Dec 29, 1988·The New England Journal of Medicine·UNKNOWN Early Breast Cancer Trialists' Collaborative Group
Feb 1, 1997·International Journal of Radiation Oncology, Biology, Physics·G E HanksL R Coia
Jul 4, 1998·International Journal of Radiation Oncology, Biology, Physics·M J ZelefskyZ Fuks
Nov 26, 1999·International Journal of Radiation Oncology, Biology, Physics·C RaschJ V Lebesque
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·J M MichalskiJ D Cox
Mar 8, 2000·International Journal of Radiation Oncology, Biology, Physics·G E HanksT Schultheiss
Jun 28, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·M J ZelefskyS A Leibel
Dec 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PollackI Rosen
Jan 5, 2002·International Journal of Radiation Oncology, Biology, Physics·Luc J BosJoos V Lebesque
May 23, 2002·International Journal of Radiation Oncology, Biology, Physics·Larry L KestinAlvaro A Martinez
Jul 20, 2002·International Journal of Radiation Oncology, Biology, Physics·Alan PollackIsaac Rosen
May 10, 2003·International Journal of Radiation Oncology, Biology, Physics·UNKNOWN ASTRO Workforce Committee
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Zvi SymonHoward M Sandler
May 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Derek B ChismAlan Pollack
Oct 7, 2004·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Peter C KoperPeter C Levendag
Mar 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Stephanie T H PeetersPeter C M Koper
Jun 7, 2005·International Journal of Radiation Oncology, Biology, Physics·Anthony L ZietmanWilliam U Shipley
Sep 20, 2005·International Journal of Radiation Oncology, Biology, Physics·Mark K BuyyounouskiAlan Pollack
Jan 18, 2006·International Journal of Radiation Oncology, Biology, Physics·Stephanie T H PeetersPeter C M Koper

❮ Previous
Next ❯

Citations

Oct 31, 2009·Australasian Physical & Engineering Sciences in Medicine·S G Williams
Oct 12, 2011·Der Radiologe·S Krause, K Herfarth
Oct 21, 2010·World Journal of Urology·Sean P Elliott, Bahaa S Malaeb
Dec 12, 2007·International Journal of Clinical Oncology·Kazuo HatanoHideyo Ishigaki
May 12, 2007·Wiener medizinische Wochenschrift·Christian Stanek
Oct 12, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Antonio José Conde-MorenoAgustín Santos-Serra
Aug 27, 2013·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·J KhalifaR de Crevoisier
Sep 28, 2013·Clinical Oncology : a Journal of the Royal College of Radiologists·N D MacdougallR Muirhead
May 20, 2008·Lancet·Jan-Erik Damber, Gunnar Aus
Jun 15, 2007·The New England Journal of Medicine·Donald S KaufmanRobert H Young
Oct 13, 2006·The New England Journal of Medicine·Thomas M Pisansky
Aug 7, 2012·Physics in Medicine and Biology·Ning WenIndrin J Chetty
Apr 8, 2010·Journal of Endourology·Tom BudihartoGyoergy Kovacs
Feb 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S X BianK E Hoffman
Jan 11, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A HorwichUNKNOWN European Society for Medical Oncology
Dec 13, 2007·Journal of the National Cancer Institute·Rune KvåleFreddie Bray
Apr 26, 2013·Journal of the National Cancer Institute·Ravi A MadanWilliam L Dahut
Aug 4, 2012·Journal of Radiation Research·Kosaku HaradaTakashi Nakano
Jun 6, 2012·Advances in Urology·Anudh K Jain, Ronald D Ennis
Nov 24, 2011·Advances in Urology·Ariel E MarciscanoNicholas Sanfilippo
Mar 31, 2012·Advances in Urology·Susan MassonAmit Bahl
Jun 2, 2012·Therapeutic Advances in Urology·David E GreeneRichard K Valicenti
Apr 30, 2010·BMC Medicine·S A Bhide, C M Nutting
Aug 3, 2012·Radiation Oncology·Reinhold GrafPeter Wust
Oct 23, 2012·Radiation Oncology·Robert L FooteRobert B Diasio
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J ZelefskyPeter T Scardino
May 24, 2014·PloS One·Ilaria NaldiCaterina Cinti
Oct 4, 2012·The Oncologist·Heather A Payne, Simon Hughes
Aug 17, 2010·Clinical Interventions in Aging·Jaspreet SinghLeonard G Gomella
Jan 29, 2013·Current Oncology·S Sridharan, P Warde
Oct 25, 2012·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Swetha Sridharan, Padraig Warde

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.